RT Journal Article
SR Electronic
T1 PrimateAI-3D outperforms AlphaMissense in real-world cohorts
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.12.24301193
DO 10.1101/2024.01.12.24301193
A1 Parry, David A.
A1 Bosc, Tom
A1 Hamp, Tobias
A1 Fiziev, Petko P.
A1 Sharma, Abhishek
A1 Kassam, Irfahan
A1 McRae, Jeremy
A1 Farh, Kyle Kai-How
YR 2024
UL http://medrxiv.org/content/early/2024/01/13/2024.01.12.24301193.abstract
AB Accurately predicting the impact of genetic variants is essential for interpreting genomic data, yet no consensus exists on how to measure classifier performance. We prepared the most comprehensive set of benchmarks to date and applied them to the recently published models PrimateAI-3D and AlphaMissense. PrimateAI-3D outperforms AlphaMissense on rare-disease cohort and biobank benchmarks, indicating that performance on clinical databases or in vitro assays does not reliably generalize to real-world cohorts.Competing Interest StatementAll authors are employees of Illumina, Inc.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Use of human data from UK Biobank was approved by the UK Biobank under application no. 33751. All other human data were obtained from datasets available to the public.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesBenchmark data used in this study will be made available upon publication.